Goldfinch Bio is a precision medicine company focused on delivering disease-modifying medicines to people with kidney disease. The company’s lead program, GFB-887, is being studied in a variety of kidney diseases.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing direct anti-viral medicines to treat infectious diseases. Atea completed its IPO on the Nasdaq stock market in October 2020.
Strateos designs, builds and operates closed loop robotic cloud labs allowing researchers to run and control automated chemical and biological workflows.
Viridian Therapeutics is a biopharmaceutical company focused on developing new treatments for patients with rare diseases. The company leverages validated biology and target/pathway with the clinical development strategy in order to deliver improvements in access, quality of life and potentially efficacy. The lead program, VRDN-001, is an anti-IGF-1R antibody in development of thyroid eye disease.
Ultivue is a spatial biology company that provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. The company’s proprietary multiplex immunofluorescence technology enables exploration and interrogation of tissue samples for precision medicine research to accelerate biomarker discovery and drug development programs.
Nuvation Bio is a clinical-stage biopharmaceutical company developing oncology medicines targeting critical pathways in cancer biology. The company has a pipeline with multiple wholly owned programs, the lead program being a selective BET inhibitor.
Nikang Therapeutics is a clinical-stage biotechnology company focus on the development of small molecule medicines for the treatment of cancers. The company is adopting target selection and medicinal chemistry approaches to develop precision oncology drugs.
Nautilus Biotechnology is developing a proteomics platform enabling the detection of proteins with single molecule sensitivity. The company aims to accelerate science research, improve the success rate of therapeutic development and enhance opportunities for personalized and predictive medicine.
Rapid Micro Biosystems is a provider of the fully automated, high-volume and secure Microbial Quality Control solution for pharmaceutical manufacturing (primary focus), food and beverage safety, personal care manufacturing, environmental water sector, industrial processing and diagnostics. The company completed its IPO on the Nasdaq stock market in July 2021.
MedAvail is a technology-enabled pharmacy organization that provides in-clinic pharmacy services through its proprietary robotic dispensing platform and home delivery operations to Medicare clinics. The company seeks to help physicians and patients to optimize drug adherence, resulting in better health outcomes.
